Cite
HARVARD Citation
Akamatsu, H. et al. (n.d.). 421PEGFR mutation analysis for prospective patient (pt) selection in AURA3 Phase III trial of osimertinib vs platinum-pemetrexed (plt-pem) in pts with EGFR T790M positive advanced non-small cell lung cancer (NSCLC). Annals of oncology. p. . [Online].